• E. Hackenthal
Part of the Springer-Lehrbuch book series (SLB)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–827Google Scholar
  2. Alderman MH (1992) Prevention of mycardial infarction. Am J Cardiol 70:21D–28DPubMedCrossRefGoogle Scholar
  3. Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC (1994) Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol 24:555–566PubMedCrossRefGoogle Scholar
  4. Antiplatelet Trialists’ Collaboration. (1994) Collaborative overviews of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106CrossRefGoogle Scholar
  5. Azetylsalizylsäure (ASS) als therapeutisches Prinzip bei kardiovaskulären Erkrankungen. Arzneimittelbrief 27:41–44Google Scholar
  6. Belardinelli L, Linden R, Berne RM (1989) The cardiac effects of adenosine. Progr Cardiovasc Dis 32:73–97CrossRefGoogle Scholar
  7. Bennett BM, McDonald BJ, Nigam R, Simon WC (1994) Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci 15:245–249PubMedCrossRefGoogle Scholar
  8. Berlin JA, Colditz GA (1990) A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 132:612–628PubMedGoogle Scholar
  9. Bertolet BD, Pepine CJ (1995) Daily life cardiac ischaemia. Should it be treated? Drugs 49:176–195PubMedCrossRefGoogle Scholar
  10. Cambien F, Poirier O, Lecerf L et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 339:641–644CrossRefGoogle Scholar
  11. Campbell CA, Przyklenk K, Kloner RA (1986) Infarct size reduction: A review of the clinical trials. J Clin Pharmacol 26:317–329PubMedGoogle Scholar
  12. Cody RJ (1984) Angiotensin II as a mediator of vasoconstriction in heart failure. Am J Med 108:81–89Google Scholar
  13. Cody RJ (1994) Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction. Arch Intern Med 154:2029–2036PubMedCrossRefGoogle Scholar
  14. Cook NS, Ubben D (1990) Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 11:444–451PubMedCrossRefGoogle Scholar
  15. Davies MK (1994) Effects of ACE inhibitors on coronary haemodynamics and angina pectoris. Br Heart J [Suppl] 72:52–56Google Scholar
  16. Dzau VJ (1988) Cardiac renin-angiotensin system: molecular and functional aspects. Am J Med 84 [Suppl 3A]:22–27PubMedCrossRefGoogle Scholar
  17. Dzau VJ, Re R (1994) Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 89:493–498PubMedGoogle Scholar
  18. Frampton J, Buckley MM, Fitton A (1992) Nicorandil. Drugs 44:625–655PubMedCrossRefGoogle Scholar
  19. Fung HL (1993) Clinical pharmacology of organic nitrates. Am J Cardiol 72:9C–15CPubMedCrossRefGoogle Scholar
  20. Garber CE, Barbour MM, Malkin RD, Ahlberg AW (1994) Role of endogenous opioids in the determination of anginal pain. Amer J Cardiol 74:815–817PubMedCrossRefGoogle Scholar
  21. Grover GJ, Sleph PG, Dzwonczyk S, et al (1993) Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Pharmacol Exp Ther 257:919–929Google Scholar
  22. Gruppo Italiano per lo Studio Sopravivenca nell’Infarto Miocardio) GISSI-3 (1994) Effects of lisinopril and transdermal glycerol trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115–1123Google Scholar
  23. Hollingshead LM, Faulds D, Fitton A (1992) Bepridil. Drugs 44:835–857PubMedCrossRefGoogle Scholar
  24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected cute myocardial infarction: ISIS-2. Lancet II:349–360Google Scholar
  25. ISIS-4 Collaborative Group (1993) ISIS-4: randomized study of oral Captopril in over 50.000 patients with suspected acute myocardial infarction. Circulation 88 [Suppl 1]:1–394Google Scholar
  26. Johnston GD (1989) Digoxin after myocardial infarction. Does it have a role? Drugs 37:577–582PubMedCrossRefGoogle Scholar
  27. Kalziumantagonisten in der Therapie der koronaren Herzkrankheit (1993) Arzneimittelbrief 27:65–67Google Scholar
  28. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framing-ham Study. JAMA 258:1183–1186PubMedCrossRefGoogle Scholar
  29. Kerins DM, FitzGerald GA (1991) The current role of platelet-active drugs in ischaemic heart disease. Drugs 41:665–671PubMedCrossRefGoogle Scholar
  30. Kjekhus K, Swedberg K (1993) ACE inhibitors after myocardial infarction. N Engl J Med 328:068–969Google Scholar
  31. Koronare Herzkrankheit. Neue Richtlinien der Europäischen Atherosklerosegesellschaft zur Prävention (1993) Med Monatsschr Pharmacol 16:210–213Google Scholar
  32. Langenfeld H (1993) β-Rezeptorenblocker bei frischem Myokardinfarkt. Dtsch Med Wochenschr 118:1569–1574PubMedCrossRefGoogle Scholar
  33. Lewis HD, Davis JW, Archibald DG, (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403PubMedCrossRefGoogle Scholar
  34. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B (1994) Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056–2069PubMedGoogle Scholar
  35. Ma SX, Schmid PG Jr, Long JP (1994) Noradrenergic mechanisms and the cardiovascular actions of nitroglycerin. Life Sci 55:1595–1603PubMedCrossRefGoogle Scholar
  36. Meredith IT, Anderson TJ, Uehata A, Yeung AC, Selwyn AP, Ganz P (1993) Role of endothelium in ischemic coronary syndromes. Am J Cardiol 72:270–320CrossRefGoogle Scholar
  37. Morgan K (1994) Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies. Br Heart J [Suppl] 72:5–10Google Scholar
  38. Nielsen FE, Gram-Hansen P, Sørensen HT, Klausen IC (1990) Pain in acute myocardial infarction. Cardiology 77:424–432PubMedCrossRefGoogle Scholar
  39. Ogilby ID, Heo AS, Iskandrian AS (1993) Effect of adenosine on coronary blood flow and its use as a diagnostic test for coronary artery disease. Cardiovasc Res 27:48–53PubMedCrossRefGoogle Scholar
  40. Parran JR (1994) Cardioprotection by angiotensin converting enzyme inhibitors — the experimental evidence. Cardiovasc Res 28:183–189CrossRefGoogle Scholar
  41. Peto R, Gray R, Collins R et al. (1988) Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 296:313–316PubMedCrossRefGoogle Scholar
  42. Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677PubMedCrossRefGoogle Scholar
  43. Ray SG, Pye M, Oldroyd KG et al. (1993) Early treatment with Captopril after acute myocardial infarction. Br Heart J 69:215–222PubMedCrossRefGoogle Scholar
  44. Richardt G, Ungerer M, Schömig A (1993) Adenosin — eine endogene protektive Substanz im Herzen. Dtsch Med Wochenschr 118:1855–1859PubMedCrossRefGoogle Scholar
  45. Rutherford JD (1995) Nitrate tolerance in angina therapy. How to avoid it? Drugs 49:196–199PubMedCrossRefGoogle Scholar
  46. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383–1389 (4 S-Study)Google Scholar
  47. Scharfstein JS, Keaney JF Jr, Silvka A et al. (1994) In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94:1432–1439PubMedCrossRefGoogle Scholar
  48. Schulz R, Triggle CR (1994) Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol Sci 15:255–259PubMedCrossRefGoogle Scholar
  49. Sleight P (1991) Cardiovascular risk factors and the effects of intervention. Am Heart J 121:990–995PubMedCrossRefGoogle Scholar
  50. Swedberg K, Held P, Kjekshus J et al. (1992) Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: result of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med 327:678–684PubMedCrossRefGoogle Scholar
  51. Tillmanns H (1992) Therapie des akuten Myokardinfarktes. Dtsch Apothekerztg 132:2612–2618Google Scholar
  52. Timmis AD, Pitt B (1994) Effects of ACE inhibitors on coronary atherosclerosis and restenosis. Br Heart J [Suppl] 72:57–60Google Scholar
  53. Todd PA, Goa KL, Langtry HD (1990) Transdermal nitroglycerin (glyceryl trinitrate). Drugs 40:880–902PubMedCrossRefGoogle Scholar
  54. Underwood MJ, More RS (1994) The aspirin papers. BMJ 308:71–72PubMedCrossRefGoogle Scholar
  55. Uren NG, Lipkin DP (1991) Silent myocardial ischaemia. Drugs 41:825–831PubMedCrossRefGoogle Scholar
  56. Vetrovec GW, Parker VE (1986) Alternative medical treatment for patients with angina pectoris and adverse reactions to β blockers. Am J Med 81 [Suppl 4A]:20–27PubMedCrossRefGoogle Scholar
  57. Williams DO, Topol EJ, Califf RM et al. (1990) Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled randomized trial. Circulation 82:376–383PubMedCrossRefGoogle Scholar
  58. Yusuf S, Lessem J, Jha P, Lonn E (1993) Primary and secondary prevention of myocardial infarction and stroke: an update of randomly allocated, controlled trials. J Hyper-tens 11 [Suppl 4]:S61–S73Google Scholar
  59. Yusuf S, Pepine CJ, Garces C et al. (1992) Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 340:1173–1178PubMedCrossRefGoogle Scholar
  60. Yusuf S, Sleight P, Held P, MacMahon S (1990) Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation 82 [Suppl II]:II117–II134PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Hackenthal

There are no affiliations available

Personalised recommendations